secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001104659-24-072821
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics cuts workforce 70% after discontinuing NP program, explores strategic alternatives
--------------------------------------------------------------------------------

- Board approved streamlined operating plan and strategic alternatives after discontinuing NP program following KOURAGE-1 Part A results on June 12, 2024.
- Workforce reduction of approximately 70%, substantially complete by June 30, 2024.
- Expects approximately $2.6M in total charges for termination benefits, recognized in Q2 and Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924072821/0001104659-24-072821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924072821/tm2417536d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-072821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer